Teva Drug Ventures' US partner Teva Drugs has announced discoveries from the Bend HD clinical preliminary of Austedo (deutetrabenazine) tablets to treat patients with chorea connected to Huntington's illness (HD).

The three-year, multicenter, single-arm, open-label, two-cohort extension trial evaluated the safety and tolerability of these patients' long-term use of Austedo.

Teva completed the preliminary in a joint effort with the Huntington Disease Clinical Trials Market.

Teva Drug Ventures' US member Teva Drugs has revealed discoveries from the Circular segment HD clinical preliminary of Austedo (deutetrabenazine) tablets to treat patients with chorea connected to Huntington's illness (HD).

The three-year, multicenter, single-arm, open-label, two-cohort extension trial evaluated the safety and tolerability of these patients' long-term use of Austedo.

In collaboration with the Huntington Study Group (HSG), Teva carried out the trial.

Eran Harary, senior vice-president, global head of Teva Specialty RD, stated: Chorea, which affects approximately 90% of HD patients, is one of the most noticeable physical manifestations of the disease.

"We're proud to share these new data to provide valuable insights for this community of patients and for those who provide care to them every day because this disease can have a significant functional impact on the lives of patients and caregivers."

Chorea is a physical manifestation of HD, which is a rare and fatal neurodegenerative disease.

Teva reported in February 2020 that the Phase II/III ARTISTS 1 and Phase III ARTISTS 2 trials of deutetrabenazine in pediatric patients with moderate to severe Tourette syndrome failed to meet the primary endpoint.